"Type 2 Diabetes: A Case for Cardiovascular Intervention" has been divided into six parts. If you have a broadband (high-speed) internet connection you can watch the program online. Please begin by clicking on Part One.

Video clips may appear jagged for the first few minutes until the entire segment has loaded.

Acknowledgement of Commercial Support
This program is funded through an educational grant from GlaxoSmithKline.

Notice of Unlabeled or Unapproved Uses
The University of Wisconsin School of Medicine and Public Health advises the audience that one or more presentations in this continuing medical education activity may contain reference(s) to unlabeled or unapproved uses of drugs or devices.

Faculty Disclosure Information
Willa A. Hsueh, M.D.
Advisory board member for: GlaxoSmithKline, Merck, Novartis. Speaker for: GlaxoSmithKline, Merck, Novartis.

Richard W. Nesto, M.D.
Honoraria: Eli Lilly, GlaxoSmithKline, Takeda Pharmaceuticals. Speaker for: Eli Lilly, GlaxoSmithKline, Takeda Pharmaceuticals.

Peter N. Weissman, M.D.
Grants/research supported by: Amylin Pharmaceuticals, AstraZeneca, Bristol-Myers Squibb Company, Eli Lilly, GlaxoSmithKline, Merck, Novartis, sanofi-aventis; Takeda Pharmaceuticals. Speaker for: Amgen Inc., Hoffmann-La Roche, GlaxoSmithKline, Merck, Pfizer, Proctor & Gamble, Takeda Pharmaceuticals.

CME Reviewer: Melissa Meredith, M.D.
No relevant financial relationship to disclose.

Part One (10 min.) Includes: CME information, faculty introductions, scope of the problem, prevalence, role of family history, susceptibility at different ages, functional abnormalities in CV system, diet and exercise as first treatment, diabetes disease progression, importance of early treatment in improving outcomes, risk factor cues for treatment. play clip

Part Two (10 min.) Includes: Patient profile: K.C. Kazarian, diagnosis and treatment paths, diabetes as a CV risk equivalent, importance of early and aggressive treatment, EMPIRE study, choices regarding drug therapy, benefits of combination therapy, value of using medications earlier, control of vascular changes associated with diabetes. play clip

Part Three (9 min.) Includes: When to switch from monotherapy to combination therapy, importance of strict monitoring and decisive changes in therapy, role of glycemic control in reducing complications, different types of combination therapy, determining which medications are appropriate for which patient, adding vs. switching medications, cardiovascular benefits of medication therapy, side-effects of each type of medication. play clip

Part Four (9 min.) Includes: Patient profile: Shirley Fields, CHF case study, deciding on combination therapy, how to monitor patients, problem of CHF in diabetic patients, PROactive study, AHA and ADA guidelines, managing TZDs and heart failure/fluid retention, assessment of risk, use of spironolactone, other cardiovascular benefits of TZDs. play clip

Part Five (9 min.) Includes: Diabetes treatment post myocardial infarction (MI), association between glucose therapy and outcomes after MI, metformin and TZD combination benefits, patient profile: Beatrice Lackey, diabetes as contributing factor for MI, cardiovascular symptoms associated with glucose intolerance, Steno-2 study. play clip

Part Six (7 min.) Includes: Data on changing macro- and microvascular events, new studies regarding TZDs effects on the pathophysiology of vascular disease, DREAM study, ADOPT study, review of key points and take-away messages, conclusion. play clip